LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
0.98
0.98
Range Annuel
0.69
3.23
Changement quotidien
-2.00%
Changement Mensuel
-1.01%
Evolution sur 6 mois
-9.26%
Changement Annuel
-67.11%
Clôture Précédente
1.0 0
Open
0.9 8
Low
0.9 8
High
0.9 8
Volume
2
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques Dividendes Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 25 September 2012

Full document

Business Context and Reporting Period

This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on September 25, 2012. The report addresses a critical regulatory event regarding the company's listing status on The NASDAQ Capital Market.

Key Financial Metrics

The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric disclosed is the stock price performance: the company's common stock closed below $1.00 per share for 30 consecutive business days, triggering a delisting warning.

Material Changes

  • Delisting Notification: On September 25, 2012, NASDAQ notified the company that it failed to regain compliance with the minimum bid price requirement within the 180-day grace period (ending September 24, 2012).
  • Listing Status: The company's common stock is now subject to delisting from The NASDAQ Capital Market unless a hearing is requested.
  • Corporate Action: The Board of Directors approved a one-for-ten reverse stock split to address the low stock price. This requires stockholder approval.
  • Stockholder Consent: Novogen Limited, holding a majority of outstanding common stock, executed a written consent to approve the amendment on September 27, 2012.

Guidance, Outlook, and Risks

  • Management Plan: The company intends to request a hearing before the NASDAQ Listing Qualifications Panel to present its plan to regain compliance. This request will automatically stay the delisting pending the Panel's decision.
  • Timeline: The reverse stock split is expected to become effective by early November 2012, subject to the mailing of a definitive information statement and the 20-day waiting period.
  • Risks and Contingencies:
    • There is no assurance that the Panel will grant an exception to continue the listing for an additional 180 days (through March 24, 2013).
    • There is no assurance that the reverse stock split will be consummated or achieve its intended effect of raising the stock price above $1.00.
    • The company reserves the right to abandon the reverse stock split at any time prior to filing the amendment with the Delaware Secretary of State.

Investor Verification Checklist

  • Verify the status of the hearing request before the NASDAQ Listing Qualifications Panel.
  • Monitor the filing and mailing of the definitive information statement regarding the reverse stock split.
  • Confirm the effective date of the one-for-ten reverse stock split and the resulting share count.
  • Check the post-split trading price to ensure it meets the $1.00 minimum bid requirement.
  • Review the final decision of the NASDAQ Panel regarding the listing exception.